Reference : Adrenomedullin refines mortality prediction by the BODE index in COPD - The "BODE-A" ...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/167602
Adrenomedullin refines mortality prediction by the BODE index in COPD - The "BODE-A" index.
English
Stolz, Daiana [> >]
Kostikas, Kostantinos [> >]
Blasi, Francesco [> >]
Boersma, Wim [> >]
Milenkovic, Branislava [> >]
Lacoma, Alicia [> >]
LOUIS, Renaud mailto [Centre Hospitalier Universitaire de Liège - CHU > > Pneumologie-Allergologie >]
Aerts, Joachim G. [> >]
Welte, Tobias [> >]
Torres, Antoni [> >]
Rohde, Gernot G. U. [> >]
Boeck, Lucas [> >]
Rakic, Janko [> >]
Scherr, Andreas [> >]
Hertel, Sabine [> >]
Giersdorf, Sven [> >]
Tamm, Michael [> >]
Feb-2014
European Respiratory Journal
European Respiratory Society
Yes (verified by ORBi)
International
0903-1936
1399-3003
Lausanne
Switzerland
[en] Biomarker ; COPD ; PROMISE-COPD study ; multidimensional assessment ; outcome
[en] The BODE index is well-validated for mortality prediction in COPD. Concentrations of plasma proadrenomedullin, a surrogate for mature adrenomedullin, independently predicted 2-year mortality among inpatients with COPD exacerbation.We compared accuracy of initial proadrenomedullin level, BODE, and BODE components, alone or combined, in predicting 1-year or 2-year all-cause mortality in a multicenter, multinational observational cohort with stable, moderate to very severe COPD.Proadrenomedullin was significantly associated (P<0.001) with 1-year mortality (4.7%) and 2-year mortality (7.8%), and comparably predictive to BODE regarding both (C statistics: 0.691 vs. 0.745, 0.635 vs. 0.679). Relative to using BODE alone, adding proadrenomedullin significantly improved 1-year and 2-year mortality prognostication (C statistics: 0.750, 0.818; both P<0.001). Proadrenomedullin plus BOD was more predictive than was the original BODE including 6-minute-walk distance. In multivariable analysis, proadrenomedullin (LR X2 13.0, P<0.001), body mass index (8.5, P=0.004), and 6-minute-walk distance (7.5, P=0.006), but not modified MMRC dyspnoea score (2.2, P=0.14) or FEV1 % predicted (0.3, P=0.60), independently foretold 2-year survival.Proadrenomedullin plus BODE better predicts mortality in COPD patients than does BODE alone; proadrenomedullin may substitute for 6-minute-walk distance in BODE when 6-minute-walk testing is unavailable.
http://hdl.handle.net/2268/167602
10.1183/09031936.00058713
http://erj.ersjournals.com/content/43/2.toc

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Adrenomedullin refines mortality prediction by the BODE_Stolz_14_EurRespJ.pdfPublisher postprint417.37 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.